Patents by Inventor Peter Findeisen

Peter Findeisen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8435757
    Abstract: The activity of a selected endopeptidase in a body fluid is determined by the mass spectrometric measurement of the reaction products of reporter substrate molecules added to the body fluid. Each reporter substrate molecule includes a peptide with the cleavage motif of the endopeptidase, an anchor group A1 on one side of the cleavage site and a different anchor group A2 on the other side of the cleavage site. One anchor is used to extract the reporter substrate molecules from the body fluid and the other anchor is used to extract digest fragments of the reporter molecules from the body fluid. Mass markers allow several reporter substrates to be used simultaneously in the same body fluid sample to measure the activity of different types of endopeptidase.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: May 7, 2013
    Assignee: Bruker Daltonik, GmbH
    Inventors: Peter Findeisen, Michael Neumaier
  • Publication number: 20100317044
    Abstract: The activity of a selected endopeptidase in a body fluid is determined by the mass spectrometric measurement of the reaction products of reporter substrate molecules added to the body fluid. Each reporter substrate molecule includes a peptide with the cleavage motif of the endopeptidase, an anchor group A1 on one side of the cleavage site and a different anchor group A2 on the other side of the cleavage site. One anchor is used to extract the reporter substrate molecules from the body fluid and the other anchor is used to extract digest fragments of the reporter molecules from the body fluid. Mass markers allow several reporter substrates to be used simultaneously in the same body fluid sample to measure the activity of different types of endopeptidase.
    Type: Application
    Filed: May 24, 2010
    Publication date: December 16, 2010
    Applicant: Bruker Daltonik GmbH
    Inventors: Peter Findeisen, Michael Neumaier
  • Patent number: 7662595
    Abstract: The present invention provides a method for assessment of the Microsatellite Instability (MSI) status of medically relevant conditions associated with MSI phenotype such as e.g. neoplastic lesions. The method is based on the analysis of a monomorphic T25 (CAT25) mononucleotide repeat located in the 3?-UTR of the Caspase 2 (CASP2) gene. Based on the determination of the length of the named mononucleotide repeat the presence or absence of MSI may be assessed. Determination of the length is performed in a single PCR procedure. Alternatively an enhanced assessment could be performed by combining the CAT25 marker with further markers such as BAT25 and BAT26 in a single multiplex PCR process.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: February 16, 2010
    Assignee: MTM Laboratories, AG
    Inventors: Peter Findeisen, Sabine Merx, Matthias Kloor, Magnus Von Knebel Doeberitz
  • Publication number: 20080096197
    Abstract: The present invention provides a method for assessment of the Microsatellite Instability (MSI) status of medically relevant conditions associated with MSI phenotype such as e.g. neoplastic lesions. The method is based on the analysis of a monomorphic T25 (CAT25) mononucleotide repeat located in the 3?-UTR of the Caspase 2 (CASP2) gene. Based on the determination of the length of the named mononucleotide repeat the presence or absence of MSI may be assessed. Determination of the length is performed in a single PCR procedure. Alternatively an enhanced assessment could be performed by combining the CAT25 marker with further markers such as BAT25 and BAT26 in a single multiplex PCR process.
    Type: Application
    Filed: October 19, 2005
    Publication date: April 24, 2008
    Inventors: Peter Findeisen, Sabine Merx, Matthias Kloor, Magnus Von Knebel Doeberitz